Drug Target Review Podcast
VitenskapPodcast by Drug Target Review
Siste episoder av Drug Target Review Podcast podcast
- Plasmids: Tackling Supply Chain and Manufacturing Challenges (00:25:02)
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments. Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories. Matthew will explore: - Strategies for providing plasmids across all necessary grades, ensuring quality and consistency. - How process standardization can significantly simplify complex supply chains. - The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues. - How these integrated approaches collectively streamline operations and accelerate gene therapy advancements. - His expert insights on the future trajectory of gene therapy.
- ranslating Promising Drug Candidates from Preclinical Screening to Clinical Trials (00:15:42)
This episode, 'Translating Promising Drug Candidates from Preclinical Screening to Clinical Trials,' will explore the challenges and successes of moving promising drug candidates from preclinical screening to clinical trials in oncology. Join Dr. Steve Shnyder, Associate Professor at the Institute of Cancer Therapeutics, University of Bradford, as he explores: - The unique challenges in oncology drug development. - Preclinical model limitations and needed innovations. - Translating preclinical insights into effective clinical trial design. - The role of AI and machine learning in overcoming development hurdles. - Real-world case studies of successful oncology drug approvals.
- Machine Learning and AI in Enhancing Image Analysis of 3D Samples (00:24:31)
In this episode, we examine how machine learning and artificial intelligence (AI) are becoming essential tools for improving image analysis of 3D samples. These technologies are reshaping research workflows by making analysis faster and more insightful. We speak with Professor Jens Christian Schwamborn, Professor of Cellular and Developmental Biology at the University of Luxembourg, and Professor Christophe Deben, Professor of Tumour Biology and Organoids at the University of Antwerp. They share their perspectives on the current challenges in 3D sample analysis and how AI is helping to solve them - reducing processing time and revealing previously inaccessible information. We'll look at the key reasons behind AI’s growing use in 3D image analysis, identify the limitations of existing imaging technologies, and explore how AI is evolving to handle increasingly complex data. We'll also discuss how the availability of large datasets is accelerating this shift and what breakthroughs AI could enable in the near future.
- Overcoming obstacles in personalised medicine (00:33:33)
In this episode, we explore the key challenges hindering the widespread adoption of personalised medicine and discuss how overcoming these barriers could transform the future of healthcare. Featuring insights from Seth Lederman, co-founder, CEO, and Chairman of Tonix Pharmaceuticals, and Steve Gardner, CEO of Precision Life and Chair of the UK Bioindustry Association Genomics Board, this conversation addresses the critical issues shaping the field. Topics include the necessary adaptations in healthcare systems to support this shift, the ethical concerns surrounding patient data privacy and genetic information, and the groundbreaking advancements anticipated in the near future.
- Leveraging “omics” for novel microbiome drug concepts (00:16:54)
In this episode, we will discuss how can we leverage microbiomics to translate gut microbiome findings into new therapeutic options
- Highlights Of The AAPS 2024 Summer Scientific Forum (00:17:02)
In this episode, we discuss the history of the AAPS Summer Scientific Forum, highlights from the 2024 event, and its goals for the future.
- Scaling genetic medicine with tRNA (00:14:26)
In this episode, we will discuss the unique biology of tRNA and how it can be leveraged to scale the development of genetic medicines. This conversation features Michelle Werner, CEO of Alltrna and CEO-Partner at Flagship Pioneering, and Caroline Köhrer, Vice President, Discovery Platform at Alltrna.
- Combatting disease with antibody drug conjugates (00:30:02)
In this podcast episode, we will be investigating the key considerations in selecting an antibody for use in antibody drug conjugates (ADCs). Also, we will be discussing the preclinical models used to evaluate the pharmacokinetics and pharmacodynamics of ADCs. This conversation features Dr Philipp Spycher, CSO and co-founder at Araris Biotech, and Dr Rebecca Boohaker, Director of Oncology at Southern Research.
- Advanced techniques in toxicity testing (00:28:12)
In this episode, we explore advanced toxicity testing methods to enhance the predictivity and reliability of toxicity assessments. This conversation features Professor Ruth Roberts, co-director and co-founder at ApconiX and Dr Oksana Sirenko, Senior Scientist at Molecular Devices.
- How mRNA technology could revolutionise therapeutics (00:31:30)
In this podcast episode, we will be discussing how mRNA vaccines for cancer treatment engage with the immune system to illicit an anti-tumour response, how they could synergise with other cancer treatments, as well as which cancers show most promise for this approach. This conversation features Dr Rebecca Boohaker, Director of Oncology at Southern Research, and Fusataka Koide, Senior Director of Business Development at Southern Research.
- Small molecules for regenerative medicine (00:19:54)
In this podcast episode, we will be discussing how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy, focusing on degenerative muscle diseases. This conversation features Frank Gleeson, CEO and co-founder of Satellos, and Dr Michael Rudnicki, co-founder and Chief Discovery Officer at Satellos.
- Exploring the wonders of molecular biology (00:25:25)
Bringing their expertise, we are thrilled to introduce Dr Matthew Nelson, Vice President, Genetics and Genomics, Deerfield Discovery and Development and CEO at Genscience and Dr Jake Rubens, President of Quotient Therapeutics and Origination Partner at Flagship Pioneering. Key discussion points: DNA has been called the code of life. How much of this code have we deciphered? How is technology evolving to allow us to better understand the consequences of genetic changes (DNA mutations, epigenetics, etc.) and health and disease? What impact do we expect this to have in drug discovery? How do we go from sequencing the DNA of individuals to making connections to health and disease? What are some examples of gene-disease links we’ve made that have informed drug target selection? This podcast is in association with Molecular Devices. With its innovative life science technology, Molecular Devices makes scientific breakthroughs possible for academic, pharmaceutical, government and biotech customers. Head to moleculardevices.com to find out more.
- Investigating the promising future of organoids (00:55:20)
In this podcast episode, titled ‘Investigating the promising future of organoids’, we will be discussing the ways in which organoids are being used to study diseases and improve drug development. We explore the specific preclinical models organoids are replacing, the current limitations of organoids and how to overcome these, as well as where the field is heading. This conversation features Dr Radhika Menon, Senior Scientist of Neurobiology at Ncardia, Dr Etienne De Braekeleer, Senior Research Scientist at AstraZeneca, and Dr Paige Vinson, Director of High Throughput Screening at Southern Research.
- Breaking resistance – the future of immunotherapy in oncology (00:25:58)
In this podcast episode titled 'Breaking resistance - the future of immunotherapy in oncology' we will be discussing checkpoint inhibitors in cancer therapy, and how primary and secondary treatment resistance are still limiting their clinical success in a variety of cancer types. In this episode, we want to explore the current status and potential solutions to addressing this major hurdle in oncology. This conversation features Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm, and Roy Baynes, Chief Scientific Officer at Eikon Therapeutics.
- CRISPR/Cas: exploring its impact on gene editing (00:25:46)
In this episode titled: CRISPR/Cas: exploring its impact on gene editing, we explore the latest technological advancements in the field and more. This conversation features Dr Pietro De Angeli, Scientist at Tubingen University Hospital, and Dr Maarten Guerts, Postdoctoral Fellow at the Princess Maxima Center for Pediatric Oncology. Key learning points: What comparative safety profiles exist between utilising plasmid DNA, mRNA, and ribonucleoproteins (RNPs) as delivery systems for CRISPR/Cas components in gene editing therapies? In what ways might the use of different ex-vivo applications affect the scalability and feasibility of large-scale gene editing treatments? How might the convergence of CRISPR/Cas technology with Artificial Intelligence/Machine Learning improve precision medicine?
- High-throughput screening: rapid advancements in drug discovery (00:21:34)
In this episode titled: High throughput screening: rapid advancements in drug discovery, we explore the latest technological advancements in the field and more. This conversation features Dr Luke Alderwick, Senior Group Leader in HTS/Hit ID at Early Discovery at Charles River Laboratories (CRL), and Dr Sachin Mahale, Research Leader in High Throughput Screening at Charles River Laboratories.
- Navigating the neurological frontier - 2024 and beyond (00:23:51)
As we step into the new year, we explore research insights and projections for the field in 2024 in neuroscience. In this episode titled: Navigating the neurological frontier - 2024 and beyond, we want to find out what are the most exciting recent advancements in neuroscience, setting the stage for the future. This conversation features Dr Alessio Travaglia, Director, Translational Science at the Foundation for National Institutes of Health (FNIH), and Dr Steve Hoffman, Associate Vice President, Science Partnerships, Translational Science, and Director of the Biomarkers Consortium at the Foundation for the National Institutes of Health (FNIH).
- Episode 24 - Genetic engineering for allogeneic immunotherapy aevelopment (00:22:43)
In this episode titled: Genetic engineering for allogeneic immunotherapy development, sponsored by Cellistic, we are taking a dive into genetic engineering, its role and relationship with allogeneic immunotherapy. This conversation features Dr Suzanne Snellenberg, Director of Genome Engineering at Cellistic, and Dr Matt Angel, CEO of Eterna Therapeutics.
- Episode 23 - Making organoids ready for screening (00:33:35)
In this episode titled: Making organoids ready for screening, sponsored by Revvity, we are understanding why researchers are turning to 3D Organoids and how organoids can be made ready for screening. This conversation features Dr Nathan Gödde, Manager of the Australian Organoid Facility at The University of Queensland and Dr Amee George, Manager of the ANU Centre of Therapeutic Discovery at the Australian National University.
- Episode 22 - Unravelling the tumour microenvironment in immuno-oncology (00:38:59)
A new episode of our podcast is now live! Sponsored by Molecular Devices, we will be discussing the tumour microenvironment in immuno-oncology. We will be covering the key themes of the tumour cells interacting with immune cells and these factors that can affect tumour fate and progression.
- Episode 21 - Exploring allogeneic cell therapies and the immune system's Impact (00:39:18)
This episode is the second part of our series: Cell Talk: A Comprehensive Guide to Next-Gen Cell Therapy. We are defining allogeneic cell therapy as the administration of cells to a patient for therapeutic use, that were not initially taken from that patient. This conversation features Andy Holt, CCO at Cellistic, and Dr Tracey Lodie, CSO at Quell Therapeutics. Key learning points: Specific roles of different immune cells in combating diseases Autologous vs allogeneic therapies Cell therapies for cancer treatment and diseases
- Episode 20 - Regulations on artificial intelligence - impact on drug discovery (00:29:43)
In this episode, we’ll be discussing the hot topic that is AI and how AI technology is used in drug discovery, looking specifically at how Biotech & Pharma trying to keep up with emerging technology. This conversation features Dr Aaron Daugherty most recently Vice President at Aria Pharmaceuticals, and Sheraz Gul, Head of Drug Screening & Compound Repurposing at Fraunhofer Institute for Translational Medicine & Pharmacology. Key learning points: -How Biotechs & Pharma are trying to keep up with AI -AI regulation -Quantitative vs Qualitative data
- Episode 19 - A current look into adoptive cell therapies (00:28:58)
Part 1 of our new series: Cell Talk: A Comprehensive Guide to Next-Gen Cell Therapy, is now live! In this episode titled: A current look into adoptive cell therapies, sponsored by Cellistic, we analyse the current landscape of adoptive cell therapies and discuss how it differs from other cancer treatments. This conversation features Stefan Braam, CTO at Cellistic, and Dr Jo Brewer, CSO at Adaptimmune.
- Episode 18 – Scaling up organoids (00:26:43)
The final episode of our Organoids Miniseries is now live! In this episode, sponsored by Molecular Devices, we discuss the processes involved in scaling up three-dimensional (3D) organoids. This conversation features Dr Vicky Marsh Durban, Chief Executive Officer at Cellesce Limited, and Dr Magdalena Kasendra, who is the Director of Research and Development at Centre for Stem Cell and Organoid Medicine. Key learning points: ● Process of scaling up 3D high-throughput cell cultures ● Induced pluripotent stem cells (iPSCs) versus adult stem cells ● Discover different kinds of solutions to overcome challenges related to scaling up 3D organoids.
- Episode 17 – Imaging: data analysis of organoids (00:32:17)
Part three of our Organoids Miniseries is now live! In this episode, sponsored by Molecular Devices, we discuss how to analyse complex data obtained from organoids. This conversation features Dr Angeline Lim, a Senior Applications Scientist at Molecular Devices and Dr David Egan, Co-founder and CEO of Core Life Analytics. Key learning points: - Examine the differences between analysing three-dimensional and two-dimensional cell models - Learn about the various types of resources required to analyse organoids - Discover different kinds of technology to overcome challenges related to data analysis of organoids. Our speakers: Dr Angeline Lim is a Senior Applications Scientist at Molecular Devices where she specialises in bioimaging and automation. She provides scientific support for the company’s portfolio of ImageXpress® High-Content Imaging Systems and their applications in lab automation, high-throughput phenotypic profiling and 3D models in biology. She has over 10 years of research experience in genetics and cell biology and holds a PhD from the University of California at Santa Cruz, US. Dr David Egan is Co-founder and CEO of Core Life Analytics, a company dedicated to helping biologists analyse their own data. David Egan has over 20 years of experience in high-throughput screening services in both academia and industry. As he witnessed his clients struggle with the analysis of data from high-content screens, he realised this was a widespread problem. This inspired the development of StratoMineR; an intuitive tool that helps biologists to independently analyse their complex datasets.